Case Report: Ivonescimab in EGFR-mutant lung cancer with baseline malignant pleural effusion and acquired complex resistance

BackgroundPatients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) presenting with malignant pleural effusion (MPE) at diagnosis have a poor prognosis. Options are limited after EGFR-TKI resistance. Ivonescimab, a PD-1/VEGFA bispecific antibody, is effective in advance...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Zeming Mo, Honglian Jiang, Lei Zhou, Qiaoya Ren, Gang Shen, Lie Li, Xiaobin Jian, Hua Yang, Yuju Bai, Mi Meng, Sisi He
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2025-12-01
coleção:	Frontiers in Immunology
Assuntos:	case report EGFR mutation ivonescimab lung adenocarcinoma malignant pleural effusion
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1725067/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!